General Information of This Payload
Payload ID
PAY0THITY
Name
MLN8237
Synonyms
MLN8237; Alisertib
   Click to Show/Hide
Target Aurora kinase A (AURKA)
Formula
C27H20ClFN4O4
Isosmiles
COC1=CC(NC2=NC3=C(CN=C(C4=C(F)C=CC=C4OC)C5=C3C=CC(Cl)=C5)C=N2)=CC=C1C(O)=O
PubChem CID
24771867
InChI
InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
InChIKey
ZLHFILGSQDJULK-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
518.932
Polar area
105.93
Complexity
1526.166082
xlogp Value
5.7461
Heavy Count
37
Rot Bonds
6
Hbond acc
7
Hbond Donor
2
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Cell-based Percent Inhibition (%) -0.14 %
Vero C1008 cells
Normal
CVCL_0574 
Cell-based Percent Inhibition (%) -0.14 %
Vero C1008 cells
Normal
CVCL_0574 
Cell-based Percent Inhibition (%) -0.23 %
Vero C1008 cells
Normal
CVCL_0574 
Cell-based Percent Inhibition (%) -0.23 %
Vero C1008 cells
Normal
CVCL_0574 
Cell-based Percent Inhibition (%) -1.282 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) -107.25 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) -11.77 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate -13 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Growth Rate -14 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cell-based Growth Rate -17 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Growth Rate -3 %
HEK-293T cells
Normal
CVCL_0063 
Cell-based Percent Inhibition (%) -3.032 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate -39 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Growth Rate -64 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Percent Inhibition (%) -7.522 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate -79 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Growth Rate -9 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Growth Rate -9 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Percent Inhibition (%) -9.458 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate -97 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Growth Rate 0 %
HEK-293T cells
Normal
CVCL_0063 
Cell-based Percent Inhibition (%) 0.8165 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) 10.02 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 10.94 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) 100 %
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell Viability (%) 103.39 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 113.91 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 116.53 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 117.66 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 120.56 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 13 %
HEK-293T cells
Normal
CVCL_0063 
Cell Viability (%) 13.71 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 14.5 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 16.14 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 16.25 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 16.37 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 16.65 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 168.73 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 169.32 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 19 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cell-based Percent Inhibition (%) 19.5 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 19.72 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) 19.91 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) 2.31 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 20.05 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 21.7 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) 24.63 %
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
Cellular activity 25 %
A549 cells
Lung adenocarcinoma
CVCL_0023 
Cell-based Growth Rate 26 %
HEK-293T cells
Normal
CVCL_0063 
Cell-based Percent Inhibition (%) 26.16 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 26.21 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 286.42 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 29.16 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 3 %
HEK-293T cells
Normal
CVCL_0063 
Cell Viability (%) 32.9 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 322.75 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 322.75 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 33 %
HEK-293T cells
Normal
CVCL_0063 
Cell Viability (%) 34.52 % Undisclosed Undisclosed Undisclosed
Maximum Effect (Emax) 37 %
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell-based Growth Rate 38 %
HEK-293T cells
Normal
CVCL_0063 
Cell-based Growth Rate 39 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cell-based Growth Rate 39 %
HEK-293T cells
Normal
CVCL_0063 
Cell-based Percent Inhibition (%) 4.436 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 41 %
U2OS cells
Osteosarcoma
CVCL_0042 
Tumor Growth Inhibition (TGI) 42 %
MM1.S cells
Plasma cell myeloma, Multiple myeloma
CVCL_8792 
Cell-based Growth Rate 43 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cell-based Growth Rate 45 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cell Viability (%) 46.57 % Undisclosed Undisclosed Undisclosed
Cell-based Percent Inhibition (%) 47.68 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 54 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cellular activity 54.2 %
A549 cells
Lung adenocarcinoma
CVCL_0023 
Cell Viability (%) 6.089 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 6.089 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 65 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cell-based Growth Rate 68 %
Fibroblast cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Cell Viability (%) 7.3 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 7.435 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 71.99 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 76.21 % Undisclosed Undisclosed Undisclosed
Cellular activity 77.2 %
A549 cells
Lung adenocarcinoma
CVCL_0023 
Cell Viability (%) 8.923 % Undisclosed Undisclosed Undisclosed
Tumor Growth Inhibition (TGI) 80 %
MM1.S cells
Plasma cell myeloma, Multiple myeloma
CVCL_8792 
Cell Viability (%) 81.61 % Undisclosed Undisclosed Undisclosed
Cell-based Growth Rate 83 %
U2OS cells
Osteosarcoma
CVCL_0042 
Cell-based Percent Inhibition (%) >90 %
NCI-H82 cells
Lung small cell carcinoma
CVCL_1591 
Cell Viability (%) 97.73 % Undisclosed Undisclosed Undisclosed
Cell Viability (%) 99.74 % Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 0.04 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 0.6 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 0.6 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1 nM
Sf9 cells
Normal
CVCL_0549 
Half Maximal Inhibitory Concentration (IC50) 1 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.1 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.2 nM
MV4-11 cells
Childhood acute monocytic leukemia
CVCL_0064 
Half Maximal Inhibitory Concentration (IC50) 1.2 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.2 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.2 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.2 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.2 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.2 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.2 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1.5 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 100 nM
NCI-H358 cells
Minimally invasive lung adenocarcinoma
CVCL_1559 
Half Maximal Inhibitory Concentration (IC50) 100 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) >10000 nM
MRC5 cells
Normal
CVCL_0440 
Half Maximal Inhibitory Concentration (IC50) >100000 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 1097.5 nM
U-266 cells
Plasma cell myeloma
CVCL_0015 
Half Maximal Inhibitory Concentration (IC50) 1100 nM Undisclosed Undisclosed Undisclosed
Half Maximal Growth Inhibitory Concentration (GI50) 12500 nM
HCT116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Growth Inhibitory Concentration (GI50) 12500 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
Half Maximal Inhibitory Concentration (IC50) 13.3 nM
Sf9 cells
Normal
CVCL_0549 
Half Maximal Inhibitory Concentration (IC50) 130 nM
MIA PaCa-2 cells
Pancreatic undifferentiated carcinoma
CVCL_0428 
Half Maximal Inhibitory Concentration (IC50) 133.5 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
Half Maximal Inhibitory Concentration (IC50) 14.5 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 15 nM
OCI-LY19 cells
Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma
CVCL_1878 
Half Maximal Inhibitory Concentration (IC50) 1500 nM
HCT116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 1533.7 nM
HeLa cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0030 
Half Maximal Inhibitory Concentration (IC50) 16 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
Half Maximal Inhibitory Concentration (IC50) 16 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 170 nM
PC-14 cells
Lung adenocarcinoma
CVCL_1640 
Half Maximal Inhibitory Concentration (IC50) >19952.62 nM
Vero C1008 cells
Normal
CVCL_0574 
Half Maximal Inhibitory Concentration (IC50) >200 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) >20000 nM
Vero C1008 cells
Normal
CVCL_0574 
Half Maximal Inhibitory Concentration (IC50) 3 nM Undisclosed Undisclosed Undisclosed
Half Maximal Growth Inhibitory Concentration (GI50) 30 nM
HCT116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 32 nM
HCT116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 320 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 32000 nM
HCT116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 330 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
Half Maximal Inhibitory Concentration (IC50) 39 nM
GSS cells
Gastric carcinoma
CVCL_8876 
Half Maximal Inhibitory Concentration (IC50) 396 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 396 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 396.5 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 396.5 nM Undisclosed Undisclosed Undisclosed
Half Maximal Effective Concentration (EC50) 40.89 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 431 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
Half Maximal Inhibitory Concentration (IC50) 48.9 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 490 nM Undisclosed Undisclosed Undisclosed
Half Maximal Growth Inhibitory Concentration (GI50) 500 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
Half Maximal Inhibitory Concentration (IC50) 502.2 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 54 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
Half Maximal Inhibitory Concentration (IC50) 6.7 nM
HeLa cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0030 
Half Maximal Inhibitory Concentration (IC50) 6.7 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 62 nM
LU-99A cells
Lung giant cell carcinoma
CVCL_1393 
Half Maximal Inhibitory Concentration (IC50) 7 nM
HCT116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 74 nM
HL-60 cells
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
CVCL_0002 
Half Maximal Inhibitory Concentration (IC50) 740 nM
HCT-15 cells
Colon adenocarcinoma
CVCL_0292 
Half Maximal Inhibitory Concentration (IC50) 77 nM
LC-2-ad cells
Lung adenocarcinoma
CVCL_1373 
Half Maximal Inhibitory Concentration (IC50) 84.2 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 90 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 90 nM Undisclosed Undisclosed Undisclosed
Half Maximal Inhibitory Concentration (IC50) 93 nM
MKN-45 cells
Gastric adenocarcinoma
CVCL_0434 
Half Maximal Inhibitory Concentration (IC50) 95 nM
HCT116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 97 nM
Cancer cells
Multiple myeloma, Plasma cell myeloma
Undisclosed
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
38751786 5D3 (CC-MLB8237)3.2-AF488 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
8.17 nM
Negative PSMA expression (PSMA-)
Method Description
The cytotoxicity of 5D3 (CC-MLN8237)3.2-AF488 was determined by treating PC3-PIP and PC3-Flu (control) cells in 96-well plates in RPMI 1640 culture media in the presence of 5D3- (CC-MLN8237)3.2-AF488 over a series of concentrations. Cells were seeded in a 96-well plate (2000 cells/well) and grown for 24 h to achieve 30%-40% confluency. Then, cells were treated with increasing concentrations of 5D3 (CC-MLN8237)3.2-AF488 or pure MLN8237 equivalent to the drug concentration in 5D3- (CC-MLN8237)3.2-AF555 (1.0 ng/mL-1.0 mg/mL by 10-fold increment). After the incubation for 72 h, IC50 values of 5D3 (CC-MLN8237)3.2-AF488 ATC and corresponding free MLN8237 were determined using the WST-8 assay (CCK-8 assay, Dojindo Molecular Technologies), following the manufacturer's protocol. Briefly, media in each well were replaced by 100 uL of the fresh media. Then, cells in each well were treated with 10 uL of WST-8 reagent and incubated at 37°C for 3 h. During incubation, WST-8 tetrazolium salt is reduced by dehydrogenase in living cells, forming a yellow formazan dye with λmax at 450 nm. After 3 h, the absorbance in wells was measured at 450 nm using a BioTek Epoch microplate spectrophotometer (Agilent Technologies). The concentration of the formazan dye in the media produced by dehydrogenases is directly proportional to the density of viable cells per well. The cell viability of treated cells was normalized to readings in untreated control cells with 100% viability. Data were fitted, and IC50 values for free MLN8237 and 5D3 (CC-MLN8237)3.2-AF488 were calculated using Prism 9 software (GraphPad, San Diego CA).

   Click to Show/Hide
In Vitro Model Prostate carcinoma PC3-PIP cells CVCL_E9XK
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
161.9 nM
Positive PSMA expression (PSMA+++/++)
Method Description
The cytotoxicity of 5D3 (CC-MLN8237)3.2-AF488 was determined by treating PC3-PIP and PC3-Flu (control) cells in 96-well plates in RPMI 1640 culture media in the presence of 5D3- (CC-MLN8237)3.2-AF488 over a series of concentrations. Cells were seeded in a 96-well plate (2000 cells/well) and grown for 24 h to achieve 30%-40% confluency. Then, cells were treated with increasing concentrations of 5D3 (CC-MLN8237)3.2-AF488 or pure MLN8237 equivalent to the drug concentration in 5D3- (CC-MLN8237)3.2-AF555 (1.0 ng/mL-1.0 mg/mL by 10-fold increment). After the incubation for 72 h, IC50 values of 5D3 (CC-MLN8237)3.2-AF488 ATC and corresponding free MLN8237 were determined using the WST-8 assay (CCK-8 assay, Dojindo Molecular Technologies), following the manufacturer's protocol. Briefly, media in each well were replaced by 100 uL of the fresh media. Then, cells in each well were treated with 10 uL of WST-8 reagent and incubated at 37°C for 3 h. During incubation, WST-8 tetrazolium salt is reduced by dehydrogenase in living cells, forming a yellow formazan dye with λmax at 450 nm. After 3 h, the absorbance in wells was measured at 450 nm using a BioTek Epoch microplate spectrophotometer (Agilent Technologies). The concentration of the formazan dye in the media produced by dehydrogenases is directly proportional to the density of viable cells per well. The cell viability of treated cells was normalized to readings in untreated control cells with 100% viability. Data were fitted, and IC50 values for free MLN8237 and 5D3 (CC-MLN8237)3.2-AF488 were calculated using Prism 9 software (GraphPad, San Diego CA).

   Click to Show/Hide
In Vitro Model Prostate carcinoma PC3-Flu cells Homo sapiens
References
Ref 1 Development and therapeutic evaluation of 5D3(CC-MLN8237)(3.2) antibody-theranostic conjugates for PSMA-positive prostate cancer therapy